Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1189 results
August 2021
-
Press Release
Novartis announces positive results from Phase III trials of Beovu® in diabetic macular edema, including dosing intervals up to 16 weeks
Results from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2 In key fluid-related… -
Ad-hoc Release
Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA
Ad hoc announcement pursuant to Art. 53 LR FDA concluded that OAV-101 intrathecal (IT) clinical program may proceed based on data from nonclinical toxicology study New Phase 3 STEER study will…
July 2021
-
Ad-hoc Release
Novartis: forte performance au deuxième trimestre, soutenue par la dynamique des marques clés de croissance; prévisions pour l’exercice 2021 inchangées
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T2 en progression de +9% (tcc1, +14% USD): Pharmaceuticals: cette unité d’affaires (UO) a vu son chiffre d’affaires progresser de… -
Ad-hoc Release
Novartis hat im zweiten Quartal dank der Dynamik wichtiger Wachstums-marken eine starke Performance erzielt; Prognose für 2021 unverändert
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz wuchs im zweiten Quartal um +9% (kWk¹, +14% USD): Die Geschäftseinheit Pharmaceuticals legte +12% (kWk, +18% USD) zu mit… -
Ad-hoc Release
Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.
Ad hoc announcement pursuant to Art. 53 LR Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21… -
Press Release
Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity
Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and… -
Press Release
Novartis announces NEJM publication of positive Phase III REACH3 data for Jakavi in chronic GvHD
REACH3 data show Jakavi significantly improved overall response rate (ORR) at week 24 (49.7% vs. 25.6%) with a higher best overall response rate (76.4% vs. 60.4%) vs. best available therapy, among…
June 2021
-
Ad-hoc Release
Novartis appoints Rob Kowalski as Chief People & Organization Officer
Basel, June 28, 2021 — Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer.… -
Press Release
Sandoz announces EU launch of ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer
Pemetrexed is indicated for patients with non-squamous Non-Small Cell Lung Cancer (NSCLC), who represent over 3 in 4 patients with lung cancer1 New ready-to-dilute format and 1,000 mg strength… -
Press Release
Positive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine
VISION manuscript shows that 177Lu-PSMA-617 plus standard of care (SOC) significantly improved overall survival and radiographic progression-free survival for patients with metastatic castration-… -
Press Release
Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts
Novartis is collaborating with Hewlett Packard Enterprise to accelerate the use of data and digital technologies within its efforts to reimagine global health and improve access to healthcare and… -
Press Release
Kesimpta® (ofatumumab) data show long-term preservation of IgG/IgM levels and no increased risk of serious infections in people living with multiple sclerosis
New ALITHIOS data show mean immunoglobulin G (IgG) levels in people treated with Kesimpta remained unchanged over 3.5 years and mean immunoglobulin M (IgM) levels remained within the reference range1…